Taking cellular immunotherapy to the next level

Glycostem Therapeutics is an innovator in cellular immunotherapy using allogeneic Natural Killer (NK) cells for treatment of leukemia, lymphoma and solid tumors.

Find out more


Glycostem is a clinical-stage company, harvesting the power of Natural Killer (NK) cells in the field of cellular immunotherapy. Using our proprietary expansion and differentiation method, we produce large amounts of NK cells from Umbilical Cord Blood stem cells. This results in products of high-quality, pure and active NK cells.

NK cells will be the new star in the domain of cellular immunotherapy. Due to their tightly regulated “natural killing”, caused by a changed balance between activating and inhibitory cellular signals and antibody dependent cellular cytotoxicity (ADCC), 

NK cells have the capability to control viral infections, target cancer and kill senescent cells. Unfortunately, our immune system can be compromised, allowing tumor cells to escape the immunological control mechanisms. Allogeneic conditions will be able to mitigate this problem. Glycostem’s clinical approach is based on this principle.  

Currently, we are clinically testing the safety and efficacy of our NK cell product in the treatment of Acute Myeloid Leukemia. 


Why NK cells?

NK cells play a fundamental role in immune surveillance. They can mediate potent anti-tumor responses without attacking normal tissues. This allows the use of these potent immune cells under mismatched conditions (allogeneic approach).  

Natural Killer Cells >

Clinical study

Glycostem’s GCT-NK cell product applied to patients suffering from Acute Myeloid Leukemia (AML).

PMLA 25 study >